

21st February 2022

RE: ORENCIA STOCK HYPERCARE PLAN (OSHP)

Dear Pharmacist,

Orencia (abatacept) subcutaneous presentations are experiencing low stock and intermittent supply risk globally. This shortage is due to a combination of manufacturing capacity constraints, supplier component challenges and shipment delays.

Due to the limited available stock of both Orencia subcutaneous presentations, the Australian Rheumatology Association (ARA) have recommended that this stock be conserved for patients who meet certain eligibility criteria. To ensure that eligible patients can access the available stock, BMS have developed the Orencia Stock Hypercare Plan (OSHP) which will be effective from the 21st of February 2022.

For the OSHP ordering process please refer to the next page.

BMS/DHL will notify you via email/iStore when the OSHP is no longer required. Should you have additional patients who wish to order Orencia during this time, we recommend that the patient consults with their physician to discuss eligibility for supply.

BMS Australia is making every effort to resolve the situation as early as possible. We know the importance of steady and reliable supply of critical medicines for patients and remain committed to delivering this medicine to patients who need it. We will continue to work closely with the TGA, ARA and Arthritis Australia to manage the shortages with the goal of minimising the impact on patients in Australia.

For enquiries please contact:

DHL Ordering
1800 077 421
d2mcs@dhl.com

BMS Medical information
1800 067 567 (select option 2)
medinfo.australia@bms.com

We thank you for your support and appreciate your patience during this period of constrained supply.

Yours sincerely,



Meredith Edwards
Associate Medical Director
Bristol-Myers Squibb Australia

ORENCIA STOCK HYPERCARE PLAN (OSHP) ORDERING PROCESS

Effective from Monday 21st February 2022 until further notice

